JP2013539781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013539781A5 JP2013539781A5 JP2013533819A JP2013533819A JP2013539781A5 JP 2013539781 A5 JP2013539781 A5 JP 2013539781A5 JP 2013533819 A JP2013533819 A JP 2013533819A JP 2013533819 A JP2013533819 A JP 2013533819A JP 2013539781 A5 JP2013539781 A5 JP 2013539781A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- medicament
- pharmaceutically acceptable
- central
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 208000004454 Hyperalgesia Diseases 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 230000002093 peripheral effect Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000035154 Hyperesthesia Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 230000000994 depressogenic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- LSUGPAVXOXLORK-UHFFFAOYSA-N n-[1-(4-cyanophenyl)-3,3-dimethyl-1-oxobutan-2-yl]-4-(6-methylpyridin-2-yl)piperazine-1-carboxamide Chemical compound CC1=CC=CC(N2CCN(CC2)C(=O)NC(C(=O)C=2C=CC(=CC=2)C#N)C(C)(C)C)=N1 LSUGPAVXOXLORK-UHFFFAOYSA-N 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39213010P | 2010-10-12 | 2010-10-12 | |
| US61/392,130 | 2010-10-12 | ||
| PCT/SE2011/051213 WO2012050512A1 (en) | 2010-10-12 | 2011-10-11 | Trpa1 receptor antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013539781A JP2013539781A (ja) | 2013-10-28 |
| JP2013539781A5 true JP2013539781A5 (enExample) | 2014-10-23 |
| JP5847827B2 JP5847827B2 (ja) | 2016-01-27 |
Family
ID=45938532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013533819A Expired - Fee Related JP5847827B2 (ja) | 2010-10-12 | 2011-10-11 | Ｔｒｐａ１受容体アンタゴニスト |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8859556B2 (enExample) |
| EP (1) | EP2627329B1 (enExample) |
| JP (1) | JP5847827B2 (enExample) |
| CN (1) | CN103153308B (enExample) |
| WO (1) | WO2012050512A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2014108885A (ru) | 2011-08-09 | 2015-09-20 | Хайдра Байосайенсиз, Инк. | Ингибирование транзиторного рецепторного потенциала ионного канала trpa1 |
| WO2013108857A1 (ja) | 2012-01-17 | 2013-07-25 | 味の素株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
| US9394308B2 (en) | 2013-01-18 | 2016-07-19 | Merck Sharp & Dohme Corp. | Inhibiting the transient receptor potential A1 ion channel |
| WO2014184248A2 (en) * | 2013-05-15 | 2014-11-20 | Acturum Life Science AB | Trpa1 antagonist compounds |
| CN103760286A (zh) * | 2014-01-14 | 2014-04-30 | 北京万全德众医药生物技术有限公司 | 一种用高效液相色谱法测定琥珀酸索非那新中间体光学纯度的方法 |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
| IT202100015098A1 (it) * | 2021-06-09 | 2022-12-09 | Flonext S R L | Composto antagonista del canale trpa1 per uso in patologie degenerative della retina |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1942106T3 (pl) * | 2003-08-01 | 2012-02-29 | Euro Celtique Sa | Środki lecznicze użyteczne do leczenia bólu |
| EP1770091A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| ES2436225T3 (es) | 2005-12-22 | 2013-12-27 | Hydra Biosciences, Inc. | Inhibidores TRPA1 para tratamiento del dolor |
| GB0614037D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| US9108905B2 (en) | 2008-01-04 | 2015-08-18 | Abbvie Inc. | TRPA1 antagonists |
| WO2010004390A1 (en) | 2008-06-17 | 2010-01-14 | Glenmark Pharmaceuticals, S.A. | Quinazoline dione derivatives as trpa1 modulators |
| TW201026700A (en) * | 2008-12-22 | 2010-07-16 | Hydra Biosciences Inc | Compositions useful for treating disorders related to TRPA1 |
-
2011
- 2011-10-11 JP JP2013533819A patent/JP5847827B2/ja not_active Expired - Fee Related
- 2011-10-11 CN CN201180049452.3A patent/CN103153308B/zh not_active Expired - Fee Related
- 2011-10-11 EP EP11832839.2A patent/EP2627329B1/en active Active
- 2011-10-11 WO PCT/SE2011/051213 patent/WO2012050512A1/en not_active Ceased
- 2011-10-11 US US13/878,862 patent/US8859556B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013539781A5 (enExample) | ||
| WO2011107608A8 (en) | Heterocyclic amides as rock inhibitors | |
| FI3256218T3 (fi) | Kdm1a-estäjät sairauksien hoidossa | |
| EP4241772A3 (en) | Process for the preparation of compounds useful for treating spinal muscular atrophy | |
| PH12015500719A1 (en) | Gdf-8-inhibitors | |
| EP4275748A3 (en) | Compositions and methods for treating cns disorders | |
| NZ703941A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| EP4227304A3 (en) | Thiadiazole analogs and their use for treating diseases associated with a deficiency of smn motor neurons | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2013509429A5 (enExample) | ||
| JP2015509534A5 (enExample) | ||
| JP2017530983A5 (enExample) | ||
| JP2017527578A5 (enExample) | ||
| MX347616B (es) | Inhibidores de csf-1r para el tratamiento de tumores de cerebro. | |
| MX2008013212A (es) | 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r. | |
| JP2017524735A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| MX2014002394A (es) | Inhibidores de rock suaves, novedosos. | |
| EP3069720A8 (en) | Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases | |
| NZ604379A (en) | Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k | |
| MX2014003408A (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1). | |
| JP2016503010A5 (enExample) | ||
| EA016687B8 (ru) | Производные циклопропиламида | |
| MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| EP4477222A3 (en) | Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt |